Search

Capacity building for ophthalmic nursing in Ghana, Botswana and Tanzania

Ophthalmic nurses (ON) have been the backbone of eye health services in Africa since the mid-20th century and remain the largest single cadre of allied ophthalmic personnel in Commonwealth countries in Africa. Numbers are currently estimated at between 3500 and...

Building capacity for diabetic retinopathy services in Malawi

Screening for diabetic retinopathy prevents blindness. There is no systematic screening programme for diabetic eye disease in Malawi and people present when they have lost vision and it is too late for treatment. The aim of the VISION 2020 LINK...

Sustainable prevention of blindness from diabetic retinopathy through prevention and control of diabetes mellitus – LINK partnership experience in Dominica

The Caribbean Diabetic Retinopathy Project (DR Caribbean) is a five-year project that aims to reduce blindness due to diabetic retinopathy (DR) across four Commonwealth countries: Belize, Dominica, Jamaica and St Lucia. The VISION 2020 LINKS Programme at the London School...

Volunteer abroad: the Khmer Sight Foundation

A team of volunteers describe their experiences of working with the Khmer Sight Foundation in Cambodia. Cambodia has a population of 15 million people, of whom an estimated 300,000 are blind. This figure is increasing by 10,000 each year. Three-quarters...

Infection prevention and control through a VISION 2020 LINK between Mombasa and Southampton

The authors share how a partnership between Mombasa and Southampton has enabled Kenyan healthcare professionals from four institutions to innovate and work as a group to improve infection prevention and control. Infection prevention and control (IPC) is a cornerstone of...

Commonwealth nations join forces to prevent blindness from diabetes

More than 70 representatives from 10 Commonwealth countries (in the African, Caribbean and Pacific regions) and Indonesia gathered at a five-day workshop in November 2014 to establish district or national plans to reduce blindness from diabetic retinopathy (DR). The event...

Post-stroke visual impairment: how big is the problem, how do we identify it, what we can do about it, and why does it matter?

In the UK, 100,000 new strokes occur each year, with 1.3 million stroke survivors [1]. This article will focus on post-stroke visual impairment, discussing topics of how common it is, how it can be detected, possible management options and how...

VISION 2020 LINKS Programme: building capacity for eye care services in Nigeria through leadership and skills development

The Lagos-Bolton VISION 2020 LINK started in December 2011. It is one of 29 LINKS now running in the VISION 2020 LINKS Programme [1]. Nigeria is the most populous country in Africa, with a current population of 178 million, projected...

Isolated trochlear (fourth cranial) nerve palsy in an Asian population

The authors report on 35 consecutive new cases of isolated fourth cranial nerve palsy seen over a period of six months in one neuro-ophthalmology clinic in Southeast Asia, with emphasis on their aetiology and management. We report on 35 patients...

What’s new in wet AMD papers?

Paper presentations on neovascular (‘wet’) age-related macular degeneration (AMD) from the 16th European Society of Retina Specialists Congress, Copenhagen, September 2016, outline recent research directions evaluating the impact of vision loss on key health domains, patient preferences in the process...

More sensitive visual acuity test for age-related macular degeneration

Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world. Primarily associated with ageing, genetic factors and lifestyle choices such as smoking also play a contributory role. Patients with early AMD, characterised by the development of...

Regulatory drug evaluations and expedited review initiatives: EU and US perspectives

The European Medicines Agency (EMA) and United States Food and Drug Administration (FDA) each conduct independent assessments of benefit-risk profile when evaluating applications to market new or modified medicines, and their respective decision-making is guided by distinct legislation, procedures and...